Adhering to Ethical Benchmarks in Neurology Clinical Trials Using iPSCs
- 204 Downloads
We examine the ethics of using induced pluripotent stem cells (iPSCs) in cell transplantation treatment of neurologic diseases and the essential types of ethical benchmarks required in clinical trials in neurology using iPSCs, including embryonic pluripotent stem cells. We focus on two issues: (1) comparison and (2) criticism of the two types of neuro-hype (neuro-purism and neuro-essentialism). In order to ensure that the dialog on ethical benchmarks continues to develop in a manner that promotes trust with society and research subjects, concerns about the clinical use of pluripotent stem cells (particularly iPSCs) in neurology must be at the forefront of any ethics discussion.
KeywordsResearch ethics Neuroethics iPS Stem cell research Bodily integrity Personal identity
Compliance with Ethical Standards
AA is the President of the Japan Association for Bioethics; this paper reflects the author’s personal academic analyses and opinions and does not represent JAB’s official position. EN and NSJ have no conflicts of interest to declare.
- 1.Center for iPS Cell Research and Application (CiRA) News. Announcement of physician-initiated clinical trials for Parkinson’s disease. http://www.cira.kyoto-u.ac.jp/e/pressrelease/news/180730-170000.html. Accessed 24 March 2019.
- 2.Nikkei Shimbun. iPS treatment: core of ‘regenerative medicine,’ challenge for recovery from spinal cord injury: Keio University protocol has been approved. February 19, 2019.Google Scholar